Warfarin vs Rivaroxaban
## Overview
Warfarin and rivaroxaban represent two generations of anticoagulation: warfarin is a vitamin K antagonist (VKA) requiring routine monitoring; rivaroxaban is a direct oral anticoagulant (DOAC) with predictable pharmacokinetics and no routine monitoring. DOACs have largely replaced warfarin for most indications in guidelines, though warfarin retains specific niches.
## Mechanism of Action
Warfarin: inhibits vitamin K epoxide reductase (VKOR/VKORC1), preventing regeneration of reduced vitamin K. This depletes vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S. Effect is delayed 2–7 days (dependent on factor half-lives).
Rivaroxaban: direct, reversible competitive inhibitor of factor Xa. Immediate anticoagulant effect with predictable dose-response.
## Pharmacokinetics and Monitoring
Warfarin: oral, highly variable PK (CYP2C9, CYP1A2, CYP3A4; VKORC1 polymorphisms), half-life ~40 h (racemic; S-warfarin active). Requires INR monitoring (target 2–3 for most, 2.5–3.5 for mechanical valves). Numerous food and drug interactions (vitamin K foods, antibiotics, antifungals, many drugs). Rivaroxaban: predictable PK, no routine monitoring, few drug interactions.
## Clinical Evidence
ROCKET-AF (rivaroxaban vs warfarin in AF): non-inferior for stroke/SE prevention, with less intracranial hemorrhage but similar major bleeding overall (more GI bleeding). Rivaroxaban is non-inferior to warfarin across VTE treatment (EINSTEIN).
## Warfarin's Remaining Niches
Mechanical heart valves: warfarin is the only anticoagulant proven safe (DOACs — specifically dabigatran — failed in RE-ALIGN trial for mechanical valves). Antiphospholipid antibody syndrome (triple-positive APLS): warfarin preferred (DOACs inferior in this high-thrombosis-risk patient group). Severe renal failure (eGFR <15): warfarin has longer safety data.
## Reversal
Warfarin: vitamin K (hours-days), PCC (prothrombin complex concentrate, minutes), FFP (minutes but large volume). Rivaroxaban: andexanet alfa (specific factor Xa reversal agent). 4F-PCC also used off-label for rivaroxaban reversal.
## Key Takeaways
- Rivaroxaban: no monitoring, predictable PK, fewer interactions, preferred for most indications
- Warfarin: mechanical valves, triple-positive APLS — irreplaceable niches
- Warfarin: lower cost in many markets; rivaroxaban generic now available
Заключение
Rivaroxaban (and DOACs generally) are preferred over warfarin for AF stroke prevention, VTE treatment, and VTE prophylaxis due to convenience, predictable pharmacokinetics, and non-inferior efficacy with favorable intracranial bleeding profile. Warfarin remains irreplaceable for mechanical heart valves and triple-positive antiphospholipid antibody syndrome.